血清miR-17-92簇在HPV陽(yáng)性宮頸癌中的早期診斷價(jià)值
發(fā)布時(shí)間：2018-11-27 16:18
【摘要】：目的檢測(cè)miR-17-92簇成員分子(miR-17、miR-18a、miR-19a、miR-19b、miR-20a和miR-92a)在人乳頭瘤病毒(HPV)陽(yáng)性宮頸癌(CC)及上皮內(nèi)瘤變(CIN)患者血清中的表達(dá)水平,并評(píng)估其對(duì)HPV陽(yáng)性宮頸癌的早期診斷價(jià)值。方法收集HPV陽(yáng)性宮頸癌患者150例(CC組)、HPV陽(yáng)性CIN1~3級(jí)患者100例(CIN組)及單純HPV陽(yáng)性或子宮良性病變者150例(對(duì)照組)血清,采用實(shí)時(shí)定量PCR(RT-q PCR)法檢測(cè)血清中miR-17-92簇成員分子的表達(dá),結(jié)合液基薄層細(xì)胞學(xué)檢測(cè)(TCT)結(jié)果,評(píng)價(jià)miR-17-92簇成員分子在HPV陽(yáng)性宮頸癌中的早期診斷價(jià)值。結(jié)果與對(duì)照組相比,miR-18a和miR-92a在CC組血清中異常高表達(dá),且其表達(dá)水平顯著高于CIN組及對(duì)照組,兩者在CIN3級(jí)患者中的表達(dá)水平及miR-18a在CIN1-2級(jí)患者中的表達(dá)水平均顯著高于對(duì)照組(P均0.05)。受試者工作曲線(ROC曲線)分析結(jié)果顯示,血清miR-18a診斷CIN3及CC(CIN3+)的曲線下面積(AUC)為0.792(95%CI:0.749~0.862),靈敏度為87%,特異度為65%;血清miR-92a診斷CIN3+的AUC為0.799(95%CI:0.744~0.847),靈敏度為55.8%,特異度為92%;TCT診斷CIN3+的AUC為0.645(95%CI:0.582~0.704),靈敏度為51.9%,特異度為77%。血清miR-18a和miR-92對(duì)宮頸癌和CIN3+的診斷效能均顯著優(yōu)于TCT檢測(cè)(P均0.01)。結(jié)論 miR-17-92簇成員分子miR-92a和miR-18a在HPV陽(yáng)性宮頸癌患者血清中高表達(dá),并可作為HPV陽(yáng)性宮頸癌的早期診斷及鑒別高級(jí)別CIN的潛在標(biāo)志物。
[Abstract]:Objective to detect the expression of miR-17-92 cluster members (miR-17,miR-18a,miR-19a,miR-19b,miR-20a and miR-92a) in the serum of patients with (HPV) positive cervical cancer (CC) and (CIN). To evaluate its value in early diagnosis of HPV positive cervical cancer. Methods Serum samples were collected from 150 patients with HPV positive cervical cancer (CC group, 100 cases of), HPV positive CIN1~3 grade patients (CIN group) and 150 cases of simple HPV positive or uterine benign lesions (control group). The expression of miR-17-92 cluster molecules in serum was detected by real-time quantitative PCR (RT-q PCR) method, and the results of (TCT) were detected by liquid-based thin layer cytology. To evaluate the value of miR-17-92 cluster molecules in early diagnosis of HPV positive cervical cancer. Results compared with the control group, the expression of miR-18a and miR-92a in serum of CC group was significantly higher than that of CIN group and control group. The expression levels of miR-18a and miR-18a in CIN3 patients and CIN1-2 patients were significantly higher than those in the control group (P < 0. 05). The results of ROC curve analysis showed that the area under the curve of serum miR-18a for the diagnosis of CIN3 and CC (CIN3) was 0.792 (95%CI:0.749~0.862), the sensitivity was 87, and the specificity was 65. The AUC of serum miR-92a for the diagnosis of CIN3 was 0.799 (95%CI:0.744~0.847), the sensitivity was 55.8 and the specificity was 92; The AUC of TCT for diagnosing CIN3 was 0.645 (95%CI:0.582~0.704), the sensitivity was 51.9 and the specificity was 77. The diagnostic efficacy of serum miR-18a and miR-92 in the diagnosis of cervical cancer and CIN3 was significantly better than that of TCT (P 0.01). Conclusion miR-92a and miR-18a are highly expressed in the serum of patients with HPV positive cervical cancer and can be used as a potential marker for early diagnosis and differential diagnosis of high grade CIN in patients with HPV positive cervical cancer.
【作者單位】： 山東大學(xué)齊魯醫(yī)院婦產(chǎn)科;平原縣第一人民醫(yī)院麻醉科;
【基金】：國(guó)家自然科學(xué)基金(81372808) 山東大學(xué)基本科研業(yè)務(wù)費(fèi)(2082015QLMS44)
【分類號(hào)】：R737.33
，
本文編號(hào)：2361420
[Abstract]:Objective to detect the expression of miR-17-92 cluster members (miR-17,miR-18a,miR-19a,miR-19b,miR-20a and miR-92a) in the serum of patients with (HPV) positive cervical cancer (CC) and (CIN). To evaluate its value in early diagnosis of HPV positive cervical cancer. Methods Serum samples were collected from 150 patients with HPV positive cervical cancer (CC group, 100 cases of), HPV positive CIN1~3 grade patients (CIN group) and 150 cases of simple HPV positive or uterine benign lesions (control group). The expression of miR-17-92 cluster molecules in serum was detected by real-time quantitative PCR (RT-q PCR) method, and the results of (TCT) were detected by liquid-based thin layer cytology. To evaluate the value of miR-17-92 cluster molecules in early diagnosis of HPV positive cervical cancer. Results compared with the control group, the expression of miR-18a and miR-92a in serum of CC group was significantly higher than that of CIN group and control group. The expression levels of miR-18a and miR-18a in CIN3 patients and CIN1-2 patients were significantly higher than those in the control group (P < 0. 05). The results of ROC curve analysis showed that the area under the curve of serum miR-18a for the diagnosis of CIN3 and CC (CIN3) was 0.792 (95%CI:0.749~0.862), the sensitivity was 87, and the specificity was 65. The AUC of serum miR-92a for the diagnosis of CIN3 was 0.799 (95%CI:0.744~0.847), the sensitivity was 55.8 and the specificity was 92; The AUC of TCT for diagnosing CIN3 was 0.645 (95%CI:0.582~0.704), the sensitivity was 51.9 and the specificity was 77. The diagnostic efficacy of serum miR-18a and miR-92 in the diagnosis of cervical cancer and CIN3 was significantly better than that of TCT (P 0.01). Conclusion miR-92a and miR-18a are highly expressed in the serum of patients with HPV positive cervical cancer and can be used as a potential marker for early diagnosis and differential diagnosis of high grade CIN in patients with HPV positive cervical cancer.
【作者單位】： 山東大學(xué)齊魯醫(yī)院婦產(chǎn)科;平原縣第一人民醫(yī)院麻醉科;
【基金】：國(guó)家自然科學(xué)基金(81372808) 山東大學(xué)基本科研業(yè)務(wù)費(fèi)(2082015QLMS44)
【分類號(hào)】：R737.33
，
本文編號(hào)：2361420
本文鏈接：http://sikaile.net/yixuelunwen/zlx/2361420.html
最近更新
教材專著
